Taxotere (docetaxel) is a popular chemotherapy drug manufactured by Sanofi-Aventis. However, the drug has been linked with permanent hair loss in women who underwent breast cancer treatment with the drug. Alopecia, or hair loss, is a common side effect of chemotherapy treatment; however, in the case of Taxotere, the manufacturer failed to warn women that the hair loss could be permanent.
Taxotere is an anti-mitotic chemotherapy medication that works by interfering with cell division. Taxotere was approved by the FDA in 1996 for treatment of locally advanced or metastatic breast cancer, and since has been approved for treatment of other forms of cancer as well. Taxotere is a member of the taxane drug class, which includes other chemotherapeutic medication, such as paclitaxel. Taxotere is twice as potent as paclitaxel, and thus, only requires treatment every three weeks, as opposed to weekly. It can often be a more convenient choice for busy women.
Studies now show that there is a link between the use of Taxotere and developing permanent alopecia, or hair loss. At McDivitt Law Firm, we feel that you deserve information that may be relevant to your rights as a consumer. We want to alert you to a potential claim regarding this medication that you or someone you know may have been prescribed.
We may be able to help you if:
- You were prescribed Taxotere for treatment of cancer, and
- Developed permanent hair loss or baldness.
If you have been adversely affected after chemotherapy treatment with Taxotere, please contact us today for a free and confidential case evaluation.